Rigel Q2 net loss narrows to $6.6M; TAVALISSE sales up 15% YoY to $21.3M

RIGEL PHARMACEUTICALS INC

2023-Q2 EPS reported -$0.12 revenue$52,956,000

Q2 net loss $6.6M ($0.04/sh) vs $13.5M loss in Q2 2022; total revenue $26.9M.
TAVALISSE net product sales $21.3M (+15% YoY); REZLIDHIA sales $2.6M with 77% sequential bottle growth.
Cash, equivalents & investments $64.4M at June 30, up from $58.2M at Dec 31, 2022.
R289 Phase 1b in LR-MDS completed cohort 2 enrollment; R552 Phase 2a in RA initiated by Eli Lilly.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RIGEL PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $26.9 million, net income net loss of $6.6 million, EPS $0.04 per basic and diluted share.

Period: the second quarter ended June 30, 2023
Revenue: $26.9 million
Net income: net loss of $6.6 million
EPS: $0.04 per basic and diluted share
Result: reported results

Exact text from the filing

For the second quarter of 2023, Rigel reported a net loss of $6.6 million, or $0.04 per basic and diluted share, compared to a net loss of $13.5 million, or $0.08 per basic and diluted share, for the same period of 2022. For the second quarter of 2023, total revenues were $26.9 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RIGEL PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue $52.9 million, net income net loss of $20.1 million, EPS $0.12 per basic and diluted share.

Period: the six months ended June 30, 2023
Revenue: $52.9 million
Net income: net loss of $20.1 million
EPS: $0.12 per basic and diluted share
Result: reported results

Exact text from the filing

For the six months ended June 30, 2023, Rigel reported a net loss of $20.1 million, or $0.12 per basic and diluted share, compared to a net loss of $40.9 million, or $0.24 per basic and diluted share, for the same period of 2022. For the six months ended June 30, 2023, total revenues were $52.9 million

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-086368

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.